NCT06227156View on ClinicalTrials.gov

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Castration-resistant Prostate Cancer
Interventions
DRUG

Disitamab Vedotin Injection

2.0 mg/kg, intravenous infusion，D1, every 2 weeks is a treatment cycle

Trial Locations (3)

100034

NOT_YET_RECRUITING

Peking University First Hospital, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

1000853

NOT_YET_RECRUITING

The Third Medical Center of PLA General Hospital, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY